<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396666</url>
  </required_header>
  <id_info>
    <org_study_id>UF 9799</org_study_id>
    <nct_id>NCT03396666</nct_id>
  </id_info>
  <brief_title>Mobile Tele-rehabilitation Solution for Obese Patients.</brief_title>
  <official_title>Impact of a Mobile Tele-rehabilitation Solution on Body Composition of Obese Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Published data indicate that rehabilitation in obese patients can result in a loss of body&#xD;
      fat and weight that is correlated to improved physical and psychological condition and&#xD;
      reduced morbidity and mortality.&#xD;
&#xD;
      the Ivestigators hypothezise that the use of a mobile telerehabilitation solution will&#xD;
      encourage the patient to adopt behavioral modifications allowing a reduction of fat mass&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is one of the most important public health care problems worldwide and is associated&#xD;
      with increased morbidity and mortality and high healthcare costs. Not all obese patients have&#xD;
      the same metabolic risk. It is pejorated in case of increase in the fat mass (FM) and&#xD;
      especially when it predominates at the visceral abdominal level.&#xD;
&#xD;
      Clinical trials have established the efficacy of lifestyle and behavioral interventions in&#xD;
      obesity.&#xD;
&#xD;
      The recent development of telerehabilitation is a promising approach that has only been the&#xD;
      subject of pilot studies Therefore, the investigators aim to test the effects of 3 months of&#xD;
      telerehabilitation solution on fat mass evaluated by impedance analysis.&#xD;
&#xD;
      The telerehabilitation program Telemouv includes physical activity sessions with low&#xD;
      intensity endurance training targeted at the level of maximal oxidation, nutritional&#xD;
      monitoring, therapeutic education tools and motivational support&#xD;
&#xD;
      Patients with BMI &gt; 30 kg/m² will be randomized for the intervention.&#xD;
&#xD;
      The investigators also will analyse the effects of the solution on different anthropometric,&#xD;
      metabolic,cardiovascular and psychological parameters, and on rest and exercise metabolism.&#xD;
      Moreover, we will assess behavioural changes in physical activity and nutrition&#xD;
&#xD;
      At the end of the study, patients in the control group will be able to benefit from the&#xD;
      telemouv solution in an ancillary study with a follow-up of three months.&#xD;
&#xD;
      For a alpha threshold of 5% and a study power of 90%, the study should include 22 patients in&#xD;
      each group. Taking in account a possible 10% of dropout the study will need to include 25&#xD;
      patients by randomized arm to demonstrate an effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Actual">June 21, 2018</completion_date>
  <primary_completion_date type="Actual">March 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modification of the amount of fat mass</measure>
    <time_frame>Month 3</time_frame>
    <description>Modification of the amount of fat mass, expressed in kilograms</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Telemouv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Regular follow-up with advice on physical activity and nutrition</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemouv</intervention_name>
    <description>Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months</description>
    <arm_group_label>Telemouv</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Body Mass Index &gt; 30 kg/m²&#xD;
&#xD;
          -  Age 20-65 years&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Unstabilized primary pathologies (cardiovascular, renal, metabolic, psychiatric)&#xD;
&#xD;
          -  No internet access at home&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

